Dashboard
Manage Tickers

CCCC C4 Therapeutics, Inc.

Nasdaq c4therapeutics.com


$ 2.49 $ 0.07 (2.94 %)    

Friday, 24-Oct-2025 17:54:39 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.25 $ 6.52 (1.07 %)
DIA $ 472.51 $ 4.92 (1.05 %)
SPY $ 677.24 $ 5.49 (0.82 %)
TLT $ 91.41 $ 0.04 (0.04 %)
GLD $ 378.38 $ -1.27 (-0.34 %)
$ 2.45
$ 2.41
$ 2.46 x 1,005
$ 2.49 x 26
$ 2.32 - $ 2.52
$ 1.09 - $ 6.52
1,810,972
na
174.37M
$ 2.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

c4-therapeutics-13g-filing-shows-point72-asset-management-lp-reports-99-passive-stake-in-co-as-of-oct-17-2025
C4 Therapeutics 13G Filing Shows Point72 A...
10/20/2025 22:19:22

- SEC Filing

c4-therapeutics-priced-an-underwritten-offering-to-institutional-investors-for-219m-shares-of-common-stock-and-pre-funded-warrants-for-up-to-287m-additional-shares
C4 Therapeutics Priced An Underwritten Off...
10/16/2025 11:10:08

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
10/03/2025 12:08:34

Core News & Articles
C4 Therapeutics Announces Clinical Trial C...
10/01/2025 11:03:16

wells-fargo-maintains-overweight-on-c4-therapeutics-raises-price-target-to-10
Wells Fargo Maintains Overweight on C4 The...
09/23/2025 12:43:52

Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
09/22/2025 17:06:11

forecasting-the-future-4-analyst-projections-for-c4-therapeutics
Forecasting The Future: 4 Analyst Projecti...
09/22/2025 13:01:10

stephens--co-reiterates-overweight-on-c4-therapeutics-maintains-6-price-target
Stephens & Co. Reiterates Overweight on C4...
09/22/2025 12:22:16

Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics (NASDAQ:CCCC) with a Overweight and maintains $6 pric...

reported-saturday-c4-therapeutics-reports-phase-1-cemsidomide-data-showing-50-response-rate-in-relapsed-refractory-multiple-myeloma-at-international-myeloma-society-meeting
Reported Saturday, C4 Therapeutics Reports...
09/22/2025 06:54:04

barclays-initiates-coverage-on-c4-therapeutics-with-overweight-rating-announces-price-target-of-8
Barclays Initiates Coverage On C4 Therapeu...
09/17/2025 10:49:28

Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Pri...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
09/15/2025 17:06:06

stephens--co-upgrades-c4-therapeutics-to-overweight-raises-price-target-to-6
Stephens & Co. Upgrades C4 Therapeutics to...
09/15/2025 13:39:06

Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics (NASDAQ:CCCC) from Equal-Weight to Overweight and raise...

guggenheim-initiates-coverage-on-c4-therapeutics-with-buy-rating-announces-price-target-of-8
Guggenheim Initiates Coverage On C4 Therap...
09/04/2025 14:03:01

Guggenheim analyst Brad Canino initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Tar...

Core News & Articles
C4 Therapeutics Highlights Biogen Collabor...
09/04/2025 11:26:02

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/07/2025 17:09:32

c4-therapeutics-q2-eps-037-beats-041-estimate-sales-6463m-beat-5240m-estimate
C4 Therapeutics Q2 EPS $(0.37) Beats $(0.4...
08/07/2025 11:13:11

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.4...

c4-therapeutics-cash-cash-equivalents-and-marketable-securities-of-2347m-as-of-march-31-2025-expected-to-provide-runway-into-2027
C4 Therapeutics' Cash, Cash Equivalents An...
05/07/2025 11:15:54

c4-therapeutics-q1-2025-eps-037-beats-047-estimate-sales-724m-beat-445m-estimate
C4 Therapeutics Q1 2025 EPS $(0.37) Beats ...
05/07/2025 11:14:53

c4-therapeutics-announces-2025-milestones-across-clinical-portfolio-of-degrader-medicines-pursuing-targets-of-high-unmet-need-in-oncology-says-cash-runway-expected-to-fund-operations-into-2027
C4 Therapeutics Announces 2025 Milestones ...
01/14/2025 12:02:04

att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday
AT&T To Rally More Than 33%? Here Are 10 T...
12/19/2024 14:32:24

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION